Meeting
2023 ASCO Annual Meeting
A multi-cohort phase I/IIa clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 administered as a monotherapy, with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors: TransStar101.
Authors
Yelena Y. Janjigian
Memorial Sloan Kettering Cancer Center, New York, NY
Yelena Y. Janjigian , Weijing Sun , Caio Max Sao Pedro Rocha Lima , Satish Shah , Aaron James Scott , Dulabh K. Monga , Madappa N. Kundranda , Amna Falak Sher , Philip Jordan Gold , Jordan Berlin , Manish R. Patel , Olatunji B. Alese , Erika P. Hamilton , Michael Cecchini , Brian Andrew Van Tine , Ben George , Rutika Mehta , Zhenzhong Xia , Caroline Germa , Nashat Y. Gabrail
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04396821
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS4176)
DOI
10.1200/JCO.2023.41.16_suppl.TPS4176
Abstract #
TPS4176
Poster Bd #
494b
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Network meta-analysis of global trials of 1L therapies in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma.
First Author: Manish A. Shah
Poster
2023 ASCO Annual Meeting
FOOTPATH: A randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naïve metastatic pancreatic cancer (mPDAC).
First Author: Benedikt Westphalen
Poster
2023 ASCO Annual Meeting
STAR-221: A randomized, open-label, multicenter, phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in previously untreated, locally advanced, unresectable or metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma.
First Author: Samuel J Klempner
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A multi-modular phase I/II study of UCB6114, a first-in-class, fully human IgG4P anti-Gremlin-1 monoclonal antibody, as monotherapy and in combination with mFOLFOX6 or trifluridine/tipiracil, for patients with advanced gastrointestinal (GI) tumors.
First Author: Debashis Sarker